Hong Kong – 17 March 2026 – Sinopharm Group Co. Ltd. (01099.HK) has released unaudited preliminary results for its Shenzhen-listed subsidiary, China National Accord Medicines Corporation Ltd. (“Sinopharm Accord”; A-share code: 000028, B-share code: 200028), covering the financial year ended 31 December 2025.
Revenue and Profitability • Revenue slipped 1.29% year on year to RMB 73.42 billion. • Operating profit jumped 163.80% to RMB 1.51 billion, while total profit advanced 162.22% to RMB 1.51 billion. • Net profit attributable to shareholders reached RMB 1.14 billion, up 76.80%. • Net profit after deducting non-recurring items rose 88.53% to RMB 1.10 billion. • Basic EPS increased 77.39% to RMB 2.04; weighted average ROE improved 2.59 percentage points to 6.26%.
Management cited a RMB 686 million reduction in impairment provisions for goodwill and intangible assets, alongside lower staff and rental expenses following store network optimisation, as key factors underpinning the stronger profitability.
Balance Sheet Highlights (end-2025) • Total assets grew 3.24% year on year to RMB 490.96 billion. • Equity attributable to shareholders increased 5.32% to RMB 186.10 billion. • Net assets per share rose 5.32% to RMB 33.44. • Share capital remained unchanged at 5.57 billion shares.
Segment Performance 1. Distribution: – Revenue: RMB 53.32 billion, up 0.64%. – Net profit: RMB 0.95 billion, up 2.94%. The distribution business remained the cornerstone of operations, supported by resource allocation and product-mix optimisation.
2. Retail (Sinopharm Holding Guoda Drugstore): – Revenue: RMB 20.98 billion, down 6.16%. – Reported net loss narrowed to RMB 0.22 billion, an 80.36% year-on-year improvement. – Excluding impairment effects, the segment delivered a net profit of RMB 0.06 billion, up 139.28%, reflecting benefits from strengthened procurement, own-brand focus and store rationalisation.
Outlook Entering 2026, the inaugural year of its 15th Five-Year Plan, Sinopharm Accord intends to prioritise “increasing revenue, reducing costs and enhancing efficiency” amid evolving market conditions, aiming for steady operational and financial progress.
The disclosed figures are preliminary and unaudited; final results will appear in Sinopharm Accord’s forthcoming 2025 annual report.